source
- Boston Scientific lowers full-year revenue outlook as restructuring plan targets slowing growthBoston Scientific announced on July 29 that it is cutting its 2026 full-year organic revenue growth forecast to 5-6%, down from the prior 6.5-8% range. The revision follows a second consecutive qu…
- Regeneron and Sanofi explore expanded partnership for Dupixent follow-on candidatesRegeneron and Sanofi said they are in early discussions about expanding their collaboration beyond the existing Dupixent partnership. The companies indicated the potential scope could include deve…